☆ 4.6 Article

Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis

BMC CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve

Tetsu Tomonari et al.

Summary: This study analyzed the association between modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) treatment for unresectable hepatocellular carcinoma (u-HCC). The results showed that patients with mALBI 1+2a had better treatment response and longer progression-free survival.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib

Atsushi Hiraoka et al.

Summary: This study compared the therapeutic efficacy of atezolizumab plus bevacizumab and lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (u-HCC). The results showed that patients who received atezolizumab plus bevacizumab had a better prognosis in terms of PFS and OS compared to those who received lenvatinib.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment

Young Eun Chon et al.

Summary: ATE+BEV regimen showed favorable efficacy and safety in patients with unresectable hepatocellular carcinoma. Blood biomarkers, such as alpha-fetoprotein and des-gamma-carboxy prothrombin, as well as the neutrophil-to-lymphocyte ratio, may be helpful in predicting survival.

CANCER MEDICINE (2023)

Add to Collection

Review Medicine, Research & Experimental

Hepatocellular Carcinoma Immunotherapy

Rubens Copia Sperandio et al.

Summary: Hepatocellular carcinoma (HCC) is a common primary liver malignancy and a leading cause of cancer-related death. Single-agent anti-PD-1 immune checkpoint inhibitors (ICIs) showed initial promise, but failed to demonstrate efficacy in phase III trials. The combination of atezolizumab and bevacizumab has been approved as first-line therapy, showing significant improvements in response rate, progression-free survival, and overall survival compared to standard treatments. Ongoing clinical trials are evaluating the use of ICIs in combination with other drugs.

ANNUAL REVIEW OF MEDICINE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy

Kazuki Maesaka et al.

Summary: In a study of 88 Japanese patients with HCC receiving atezolizumab plus bevacizumab, 10.2% of patients exhibited hyperprogressive disease (HPD) and had significantly shorter overall survival, with elevated baseline neutrophil-to-lymphocyte ratio (NLR) being identified as a risk factor for HPD.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

Makoto Chuma et al.

Summary: In patients with unresectable hepatocellular carcinoma, ATZ + BV treatment may offer significant benefits in those who meet IMbrave150 criteria or have low NLR.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma

Jaekyung Cheon et al.

Summary: This study aimed to investigate the safety and efficacy of Atezolizumab plus bevacizumab in real settings for patients with advanced hepatocellular carcinoma. The results showed that Ate/Bev demonstrated real-life efficacy and safety in Korean patients, consistent with the phase III trial results, but showed unfavorable outcomes in patients with elevated NLR.

LIVER INTERNATIONAL (2022)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies

Fabio Salvatore Macaluso et al.

Summary: Cumulative analysis of real-world studies confirms the good efficacy of TOFA in both induction and maintenance of ulcerative colitis, with a consistent safety profile.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Oncology

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

Jing-Houng Wang et al.

Summary: Atezolizumab plus bevacizumab has been approved as the first-line treatment for unresectable hepatocellular carcinoma. This study examined the efficacy and safety of this treatment in real-world clinical practice and found that it is effective and well-tolerated. In addition, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were identified as independent prognostic factors for progression-free survival (PFS).

CANCERS (2022)

Add to Collection

Article Oncology

Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma

Shohei Komatsu et al.

Summary: Atezolizumab plus bevacizumab therapy appears to be effective for advanced hepatocellular carcinoma regardless of liver function and treatment line. Lenvatinib treatment post-failure of the former therapy may also be effective, with caution needed for potential liver function deterioration.

ANTICANCER RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study

Antonio D'Alessio et al.

Summary: This study confirms the reproducible safety and efficacy of AtezoBev in routine clinical practice. Patients with impaired liver function (CP-B) showed comparable tolerability to those with normal liver function (CP-A), indicating the need for prospective evaluation in this specific population.

HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice

Takaaki Tanaka et al.

Summary: There was no significant difference in the best response between CP-A and -B patients treated with Atez/Bev. Analysis showed that CP-A patients had better progression-free survival (PFS) and overall survival (OS) rates compared to CP-B patients. The median PFS and OS were also significantly different between different Child-Pugh score (CPS) groups and modified albumin-bilirubin grade (mALBI) groups.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Article Oncology

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis

Toshifumi Tada et al.

Summary: This study demonstrates that atezolizumab plus bevacizumab can be used efficaciously and safely in elderly patients with unresectable hepatocellular carcinoma (HCC), with age not being a significant factor affecting treatment outcomes and adverse event rates.

CANCER MEDICINE (2022)

Add to Collection

Article Oncology

Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers

Vera Himmelsbach et al.

Summary: The combination therapy of atezolizumab and bevacizumab has shown high efficacy and manageable toxicity in the treatment of hepatocellular carcinoma, with better prognosis in patients with viral hepatitis.

CANCERS (2022)

Add to Collection

Article Oncology

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study

Beom Kyung Kim et al.

Summary: In the first-line treatment of unresectable HCC, ATE/BEV and LENV had comparable clinical efficacy and safety, with no significant differences observed.

CANCERS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu et al.

Summary: This study analyzed tumor samples from patients with hepatocellular carcinoma and found that combination therapy with atezolizumab and bevacizumab was effective in treating this type of cancer. Patients with high expression of VEGF Receptor 2, regulatory T cells, and myeloid inflammation signatures showed better outcomes with the combination therapy compared to atezolizumab alone. These findings provide insights into baseline immune and genetic features that can identify patients who will benefit from the combination therapy of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

NATURE MEDICINE (2022)

Add to Collection

Article Oncology

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

Takuya Sho et al.

Summary: The combination of atezolizumab and bevacizumab is equally effective for patients with unresectable hepatocellular carcinoma (HCC) who meet or do not meet the eligibility criteria of the IMbrave150 trial. However, careful monitoring of liver functional reserve is necessary for patients not meeting the trial criteria.

CANCERS (2022)

Add to Collection

Article Oncology

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi et al.

Summary: This study confirms the reproducible safety and efficacy of atezolizumab plus bevacizumab in routine clinical practice for patients with unresectable hepatocellular carcinoma. The presence of portal vein tumor thrombosis (PVTT) and higher ALBI grade are indicators of poorer survival in patients who meet the Child-Pugh-A criteria.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Gastroenterology & Hepatology

Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment

Ching-Tso Chen et al.

Summary: This study reviewed the prognosis and treatment pattern after the failure of first-line Atezo-Bev treatment in patients with advanced hepatocellular carcinoma. The study found that receiving second-line therapy and having good liver reserve were associated with favorable survival rates.

HEPATOLOGY INTERNATIONAL (2022)

Add to Collection

Article Oncology

Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience

Tiago de Castro et al.

Summary: This study evaluated the efficacy and safety of atezolizumab/bevacizumab in patients with hepatocellular carcinoma (HCC), and found that the efficacy was comparable to previous clinical trial results. Additionally, liver function scores and overall patient condition were associated with survival.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

Add to Collection

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Oncology

Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies

Xiufeng Liu et al.

Summary: Hepatocellular carcinoma is a common cancer with poor prognosis in unresectable cases. Recent studies show that combination therapy with atezolizumab and bevacizumab could be a promising future standard treatment option for these patients.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Oncology

Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma

Teiji Kuzuya et al.

Summary: This study found that early changes in alpha-fetoprotein levels may be useful for predicting treatment efficacy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. An AFP ratio of 1.4 or higher at 3 weeks could be an early predictor of refractoriness to this therapy.

ONCOLOGY (2021)

Add to Collection

Article Oncology

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Hideki Iwamoto et al.

Summary: The study retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC patients, showing that it remains effective and safe in real-world clinical practice.

CANCERS (2021)

Add to Collection

Article Oncology

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Yuji Eso et al.

Summary: Pretreatment neutrophil-to-lymphocyte ratio (NLR) may serve as a useful predictor of therapeutic response to Atezo/Bev therapy in patients with HCC, as patients who achieved disease control had significantly lower NLR values compared to those with disease progression, and patients with NLR ≤ 3.21 demonstrated significantly better progression-free survival than those with NLR > 3.21.

CURRENT ONCOLOGY (2021)

Add to Collection

Review Oncology

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab

Chiun Hsu et al.

Summary: The combination of atezolizumab and bevacizumab has emerged as the preferred first-line treatment for patients with unresectable hepatocellular carcinoma due to its positive efficacy and safety findings. Ongoing trials combining immune checkpoint inhibitors with other agents are likely to expand the range of first-line treatment options for this condition, necessitating healthcare providers to have concise information about their use and safety profiles. Increased awareness of risks associated with these therapies and knowledge of adverse event monitoring and management will be crucial as treatment options broaden for unresectable hepatocellular carcinoma.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States

Nicole E. Rich et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Michael S Lee et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Hepatocellular carcinoma: old friends and new tricks

Eunsun Kim et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2020)

Add to Collection

Review Immunology

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

Stephen P. Hack et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Systemic Treatment for Advanced Hepatocellular Carcinoma

Mohamed Bouattour et al.

LIVER CANCER (2019)

Add to Collection

Article Gastroenterology & Hepatology

Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience

Luca Rinaldi et al.

DIGESTIVE DISEASES AND SCIENCES (2019)

Add to Collection

Review Oncology

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma

Jean-Luc Raoul et al.

HEPATIC ONCOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations

Jean-Charles Nault et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Review Oncology

Emerging therapies in advanced hepatocellular carcinoma

Sowmini Medavaram et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)

Add to Collection

Article Health Care Sciences & Services

Conducting systematic reviews of association (etiology): The Joanna Briggs Institute's approach

Sandeep Moola et al.

INTERNATIONAL JOURNAL OF EVIDENCE-BASED HEALTHCARE (2015)

Add to Collection

Article Health Care Sciences & Services

Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments

Carson Ka-Lok Lo et al.

BMC MEDICAL RESEARCH METHODOLOGY (2014)

Add to Collection

Article Multidisciplinary Sciences

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst et al.

NATURE (2014)

Add to Collection

Article Oncology

Efficacy, Safety, and Biomarkers of Single- Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma

Valerie Boige et al.

ONCOLOGIST (2012)

Add to Collection

Review Biochemistry & Molecular Biology

Hallmarks of Cancer: The Next Generation

Douglas Hanahan et al.

CELL (2011)

Add to Collection

Review Surgery

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

David Moher et al.

INTERNATIONAL JOURNAL OF SURGERY (2010)

Add to Collection

Article Medicine, General & Internal

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial

JM Llovet et al.

LANCET (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.